{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06328777",
            "orgStudyIdInfo": {
                "id": "CAB-201-003"
            },
            "organization": {
                "fullName": "Cabaletta Bio",
                "class": "INDUSTRY"
            },
            "briefTitle": "RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis",
            "officialTitle": "A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Systemic Sclerosis",
            "therapeuticArea": [
                "Other"
            ],
            "study": "reset-ssc-an-open-label-study-to-evaluate-the-safety-and-efficacy-of-caba-a-car-t-cell-therapy-in-subjects-with-systemic-sclerosis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2029-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-19",
            "studyFirstSubmitQcDate": "2024-03-19",
            "studyFirstPostDateStruct": {
                "date": "2024-03-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Cabaletta Bio",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis",
            "detailedDescription": "Systemic sclerosis (SSc), also known as scleroderma , is a rare autoimmune disorder characterized by autoantibody production and abnormal B cell function. Though the cause of SSc is not well understood, it is thought to involve B cells that cause the body to attack different tissues in one's own body, causing skin and organ fibrosis. This study is being conducted to evaluate the safety and efficacy of an investigational therapy, CABA-201, a CD19-CAR T cell therapy, that can be given to patients with SSc who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated."
        },
        "conditionsModule": {
            "conditions": [
                "Systemic Sclerosis",
                "Scleroderma"
            ],
            "keywords": [
                "CABA-201",
                "autoimmune disease",
                "anti-CD19 CAR-T therapy",
                "systemic sclerosis",
                "scleroderma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "CABA-201",
                    "type": "EXPERIMENTAL",
                    "description": "Severe Skin Cohort: Infusion of CABA-201 with preconditioning in subjects with SSc with severe skin involvement\n\nOrgan Cohort: Infusion of CABA-201 with preconditioning in subjects with SSc with organ involvement",
                    "interventionNames": [
                        "Biological: CABA-201"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "CABA-201",
                    "description": "Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide",
                    "armGroupLabels": [
                        "CABA-201"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "To evaluate incidence of adverse events",
                    "description": "Incidence and severity of AEs",
                    "timeFrame": "Up to 28 days after CABA-201 infusion"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "To evaluate adverse events and laboratory abnormalities",
                    "description": "Incidence and severity of AEs, including changes in laboratory values and vital signs",
                    "timeFrame": "Up to 156 weeks"
                },
                {
                    "measure": "To characterize the pharmacodynamics (PD)",
                    "description": "Levels of B cells in the blood",
                    "timeFrame": "Up to 156 weeks"
                },
                {
                    "measure": "To characterize the pharmacokinetics (PK)",
                    "description": "Levels of CABA-201-positive T cells in the blood",
                    "timeFrame": "Up to 156 weeks"
                },
                {
                    "measure": "To evaluate efficacy",
                    "description": "Proportion of subjects achieving revised CRISS criteria",
                    "timeFrame": "Up to 156 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u226518 and \u226470\n* A clinical diagnosis of SSc, based on the 2013 American College of Rheumatology and European League Against Rheumatism classification criteria.\n* Early active disease\n* Evidence of significant skin, pulmonary, renal, or cardiac involvement\n\nExclusion Criteria:\n\n* Contraindication to leukapheresis\n* History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites\n* Active infection requiring medical intervention at screening visit\n* Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.\n* Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures\n* Severe lung or cardiac impairment\n* Previous CAR T cell therapy\n* Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Cabaletta Bio",
                    "role": "CONTACT",
                    "phone": "+1 267 759 3100",
                    "phoneExt": "4444",
                    "email": "clinicaltrials@cabalettabio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Cabaletta Bio",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Michigan",
                    "status": "RECRUITING",
                    "city": "Ann Arbor",
                    "state": "Michigan",
                    "zip": "48109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "James St. Clair",
                            "role": "CONTACT",
                            "phone": "734-936-5615",
                            "email": "ssc-coordinator@umich.edu"
                        },
                        {
                            "name": "Neda Kortam",
                            "role": "CONTACT",
                            "phone": "734-763-4866",
                            "email": "ssc-coordinator@umich.edu"
                        },
                        {
                            "name": "Monalisa Ghosh, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.27756,
                        "lon": -83.74088
                    }
                },
                {
                    "facility": "Duke University",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Khalia Stewart",
                            "role": "CONTACT",
                            "phone": "919-660-2280",
                            "email": "Khalia.stewart@duke.edu"
                        },
                        {
                            "name": "Michelle Mack",
                            "role": "CONTACT",
                            "phone": "919-613-1107",
                            "email": "Michelle.mack@duke.edu"
                        },
                        {
                            "name": "Ankoor Shah, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000012595",
                    "term": "Scleroderma, Systemic"
                },
                {
                    "id": "D000045743",
                    "term": "Scleroderma, Diffuse"
                },
                {
                    "id": "D000012598",
                    "term": "Sclerosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15415",
                    "name": "Sclerosis",
                    "asFound": "Sclerosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15412",
                    "name": "Scleroderma, Systemic",
                    "asFound": "Systemic Sclerosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M25560",
                    "name": "Scleroderma, Diffuse",
                    "asFound": "Systemic Sclerosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5565",
                    "name": "Systemic Scleroderma",
                    "asFound": "Systemic Sclerosis",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "relevance": "LOW"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}